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Outcomes and survival in surgical treatment of the descending thoracic
aorta with acute dissection
Bozinovski J, Coselli JS. Ann Thorac Surg 2008;85:965-71.
Conclusion: Open replacement of the descending thoracic aorta or
thoracoabdominal aorta for acute type B dissection carries substantial mor-
bidity and mortality rates.
Summary: In a large majority of cases, acute type B aortic dissection is
managed medically with a favorable outcome. Certainly, aortic rupture in
the setting of acute type B dissection is an indication for emergency inter-
vention. Some centers also used continued pain or a large diameter aortic
dissection as an indication for urgent repair. In this article the authors
describe the results of open urgent or emergency repair of the descending
thoracic aorta or the thoracoabdominal aorta for acute dissection in 76
consecutive patients (72% male). The patients were acquired during a
16-year period from 1989 to 2004 and therefore represent a relatively small
component of patients treated for thoracic dissection at this center during
that time. The average age of the patients who underwent surgery for acute
type B aortic dissection was 64.1 12.2 years (range, 36-86 years), and 22%
presented with rupture. A variety of surgical adjuncts were used without a
specific protocol, including hypothermic circulatory arrest in eight patients
and left carotid bypass in 15. Spinal fluid drainage was used in only five
patients. Aortic clamp time was 38.4  17.3 minutes.
One patient died intraoperatively. The overall 30-day operative mor-
tality was 22.4%. Paraplegia occurred in 6.6%, and hemodialysis was required
in 19.7%, with about half of these patients requiring permanent hemodial-
ysis. Cardiac complications occurred in 43.4%, and 10 patients had pro-
longed respirator dependence necessitating tracheostomy. The hospital stay
was 26.0  29.7 days. Rupture was not associated with an increased risk of
operative mortality or perioperative complication.
Comment: The article highlights why it is best to avoid an operation in
acute type B dissections. Even in a center with acknowledged expertise in
thoracic aortic surgery, mortality is high and morbidity is also very high.
Because mortality and morbidity rates were the same for patients with and
without rupture, it is important to reassess indications for emergency or
urgent open thoracic aortic repair in patients with acute type B dissection.
We need better natural history data to know whether continued pain
predicts rupture or if a larger initial diameter of the dissection predicts actual
rupture. One can also see this article as providing justification for endovas-
cular repair of ruptured or severely symptomatic acute type B dissections.
Given the results here, most centers are likely to do better with endovascular
repair rather than open repair of an acute type B dissection.
Telmisartan, ramipril, or both in patients at high risk for vascular
events
ONTARGET Investigators. N Engl J Med 2008;358:1547-59.
Conclusion: The angiotensin-receptor blocker (ARB) telmisartan is
equivalent to the angiotensin-converting enzyme (ACE) inhibitor ramipril
in preventing cardiovascular events in patients with vascular disease or
diabetes.
Summary: It is well known that ACE inhibitors reduce mortality and
morbidity from cardiovascular causes in patients with vascular disease or
high-risk diabetes who do not have heart failure. ARBs have also been shown
to reduce fatal and nonfatal cardiovascular events, but have not been
previously compared with ACE inhibitors in patients with peripheral arterial
disease or high-risk diabetes. In this study, the ACE inhibitor ramipril was
compared with the ARB inhibitor telmisartan and with the combination of
the two drugs in patients with vascular disease or high-risk diabetes. This was
a noninferiority study. Patients underwent a three-way, single-arm, run-in
period and then were randomized using double-blind techniques so that
8576 patients received 10 mg of ramipril daily, 8542 received 80 mg of
telmisartan daily, and 8502 received both drugs as a combination therapy.
The primary composite outcome was myocardial infarction, stroke, hospi-
talization for heart failure, or death from cardiovascular causes.
Median follow-up was 56 months. The mean blood pressure was lower
in both the telmisartan group and the combination therapy group compared
with the ramipril group. The difference was 0.9/0.6 mg Hg in the telmis-
artan group and 2.4/1.4 mm Hg in the combination therapy group com-
pared with the ramipril group. The primary endpoint occurred in 1412
patients (16.5%) in the ramipril group and in 1423 (16.7%) in the telmisar-
tan group (relative risk, 1.05; 95% confidence interval, 0.95-1.09). The
telmisartan group had lower rates of cough than the ramipril group (1.1% vs
4.2%, P .001). The telmisartan group also had a lower rate of angioedema
than the ramipril group (0.1% vs 0.2%, P  .01) but a higher rate of
hypotensive symptoms (2.6% vs 1.7%, P .001). Syncopal rate was the same
in the two groups (0.2%). In the combination therapy group, the primary
endpoint occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI,
0.92-1.07) compared with the ramipril group. The combination therapy
group had an increased risk of hypotensive symptoms (4.8 % vs 1.7%, P 
.001), syncope (0.3% vs 0.2%, P  .03), and renal dysfunction (13.5% vs
10.2%, P  .001) than the ramipril group.
Comment: The data indicate that the ARB telmisartan is equivalent to
the ACE inhibitor ramipril in patients with vascular disease or high-risk
diabetes in reducing cardiovascular events. This is the fourth trial indicating
the ARBs are equivalent to ACE inhibitors in reducing cardiovascular events.
The clinical role of ARBs is still being defined. These drugs are more costly
than ACE inhibitors and generally have more side effects. At this point their
primary value seems to be patients who cannot tolerate ACE inhibitors
because of cough.
Long-term results of carotid stenting vs endarterectomy in high-risk
patients
Grum HS, Yadava JS, Fayad P, and the SAPPHIRE Investigators. N Engl J
Med 2008;358:1572-9.
Conclusion: There is no significant difference in long-term outcomes
in patients with severe carotid artery stenosis and increased surgical risk
treated with carotid stenting and an embolic protection device vs those
undergoing carotid endarterectomy (CEA).
Summary: The Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial was designed as a noninferi-
ority trial and reported 1-year results in 2004, finding carotid artery stenting
with an embolic protection device was not inferior to CEA (N Engl J Med
2004;351:1493-501). The 3-year results are reported here. Originally, 334
patients were entered in the trial. The patients were considered at increased risk
for complications for CEA and had to have had at least 50% stenosis of the
internal carotid artery to be included. Eighty percent of the patients were
asymptomatic. Prespecified major secondary endpoints at 3 years were a com-
posite of death, stroke, or myocardial infarction30 days after the procedure,
or death or ipsilateral stroke between 31 days and 1080 days (3 years).
At 3 years, data were available for 260 patients, 85.6% of the patients in
the stented group and 70.1% of patients in the CEA group. Prespecified
major secondary endpoints occurred in 41 patients in the stented group
(cumulative index, 24.6%; Kaplan-Meier estimate, 26.2%) and in 45 patients
in the endarterectomy group (cumulative index, 26.9%; Kaplan-Meier esti-
mate, 30.3%; absolute difference in cumulative incidence for the stenting
group, –2.3%; 95% CI, 11.8-7.0). There were 15 strokes in each of the two
groups, with 11 in the stenting group and nine in the CEA group being
ipsilateral to the treated artery.
Comment: This trial has a number of significant limitations, all of
which, to the authors’ credit, are indicated on the last page of the article,
before the references. These include the absence of a medical therapy group,
the fact that many of these patients in many practices would not be treated
with any intervention, the small size of the randomized cohort that prevents
meaningful subgroup analysis, incomplete follow-up at 3 years, the use of
only one type of embolic protection device, and the lack inclusion of
moderate- or low-risk patients for CEA. Finally, 10 of the 12 named authors
are financially linked to Cordis, the sponsor of the trial, or had patents linked
to the cerebral protection device used in the trial.
Significance of postoperative cross cerebellar hypoperfusion in patients
with cerebral hyperperfusion following carotid endarterectomy:
SPECT study
Ogasawara K, Kobayashi M, Suga Y, et al. Eur J Nucl Med Mol Imaging
2008;35:146-52.
Conclusion: Postoperative crossed cerebellar hypoperfusion (CCH) in
patients with cerebral hyperperfusion after carotid endarterectomy (CEA)
results in postoperative cognitive impairment even when asymptomatic.
Summary: Cerebral hyperperfusion after CEA is defined as an increase
in ipsilateral cerebral blood flow that exceeds themetabolic demands of brain
tissue. The occurrence of the cerebral hyperperfusion syndrome is charac-
terized by headache, face and eye pain, seizure, and focal symptoms. Symp-
tomatic cerebral edema or intracerebral hemorrhage occurs less often than
cerebral hyperperfusion after CEA, much of which may be asymptomatic.
There are data to suggest post-CEA cerebral hyperperfusion, as measured by
a single-photon emission computed tomography (SPECT) scanning, can be
associated with development of postoperative cognitive impairment without
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the occurrence of clinically evident cerebral hyperperfusion. Crossed cere-
bellar hypoperfusion (CCH) is a reduction in blood flow in the cerebellar
hemisphere contralateral to a supertentorial lesion. This phenomenon can be
seen after CEA. The authors sought to clarify the significance of postoper-
ative CCH in patients with cerebral hyperperfusion using SPECT scanning
and tests of cognitive impairment.
Brain perfusion was measured using SPECT scanning before and
immediately after CEA and on postoperative day 3 in 80 patients who
underwent CEA for70% stenosis. Postoperative CCH was determined by
differences between asymmetry of perfusion in the cerebellar hemispheres
before and after CEA. Patients also underwent neuropsychologic testing
preoperatively and at 1 month after CEA.
The authors used a definition of a 100% increase in cerebral blood flow
for cerebral hyperperfusion and found that it had developed in 11 of 80
patients after CEA. SPECT scans were performed immediately after CEA
and on postoperative day 3. Of the 11 patients in whom cerebral hyperper-
fusion developed, CCHwas observed in seven on postoperative day 3. Three
patients had cerebral hyperperfusion syndrome and exhibited cerebral hy-
perperfusion and CCH on postoperative day 3, and postoperative cognitive
impairment developed. Four of eight patients with asymptomatic cerebral
hyperperfusion exhibited CCH. Three of these patients exhibited postoper-
ative cognitive impairment. The four patients with asymptomatic cerebral
hyperperfusion who did not have CCH did not experience postoperative
cognitive impairment.
Comment: Cerebral hyperperfusion after CEA is more complicated than
most are aware. The article points out that it occurs more frequently than is
generally thought, has different patterns of hyperperfusion, and can result, at
least when measured using sophisticated neuropsychiatric testing, in cognitive
impairment even in the absence of clinical hyperperfusion syndrome.
Use of multiple biomarkers to improve the prediction of death from
cardiovascular causes
Zethelius B, Berglund L, Sundstrom J, et al. N Engl J Med 2008;358:
2107-16.
Conclusion: In elderly men, use of biomarkers of cardiovascular and
renal abnormalities increases risk stratification for death from cardiovascular
causes beyond that of a predictive model using traditional risk factors only.
Summary: The authors sought to evaluate the utility of multiple
biomarkers from different disease pathways to predict the risk of death from
cardiovascular causes in elderly men. Data were acquired from the Uppsala
Longitudinal Study of AdultMen (ULSAM). This community-based cohort
study was initiated in 1970 of 50-year-old men born from 1920 to 1924 and
living in Uppsala, Sweden. This analysis is based on the third examination cycle
of this cohort when participants were approximately 71 years of age (1991 to
1995). Established risk factors for cardiovascular disease analyzed included age,
systolic blood pressure, use or nonuse of antihypertensive treatment, total
cholesterol levels, high-density lipoprotein cholesterol, use or nonuse of lipid-
lowering treatment, presence or absence of diabetes, smoking status, and body
mass index. Additional biomarkers evaluated reflected those that mirrored
myocardial cell damage, left ventricular dysfunction, renal failure, and inflam-
mation (troponin I, N-terminal pro-brain natriuretic peptide, cystatin C, and
C-reactive protein). Follow-up was for a median of 10.0 years.
There were 1135 participants (mean age, 71 years at baseline). Of
these, 315 died during follow-up, and 136 of the deaths were the result of
cardiovascular disease. All the biomarkers predicted risk of death from
cardiovascular causes according to Cox proportional hazard models and
adjusting for established risk factors. The predictive value increased signifi-
cantly when the biomarkers were incorporated into a model with established
risk factors in the entire cohort and in the group of 661 patients who did not
have cardiovascular disease at baseline (C statistic with biomarkers vs with-
out biomarkers, 0.766 vs 0.664, P  .001; C statistic with biomarkers vs
without biomarkers, 0.748 vs 0.688, P  .03).
Comment: Previous studies evaluating the combination of multiple
biomarkers in predicting cardiovascular risk (N Engl J Med 2006;355:
2631-9) have not shown as dramatic results as the current study. The
authors point out that this may be because participants in the present study
were an average of 10 years older than the participants in previous studies,
and that the combination of biomarkers used in the current study were not
used in previous studies. Biomarkers used in this study may identify patients
with functional or structural abnormalities of their cardiovascular systems
that have not yet led to overt cardiovascular disease but place the patients at
risk for the development of cardiovascular disease during follow-up.
Risk of new aneurysms after surgery for popliteal aneurysm
Ravn A, Wanhainen A, Bjorck M. Br J Surg 2008;95:571-5.
Conclusion: In patients treated surgically for popliteal artery aneu-
rysm, the development of new aneurysms at other sites during follow-up is
common.
Summary: Patients with popliteal artery aneurysms (PAA) are known
to have a high incidence of concurrent aneurysmal degeneration of the
opposite popliteal artery or the abdominal aorta, or both, at the time of
discovery of the index PAA. The risk of developing new aneurysms in
previously apparently normal arterial segments after PAA repair is, however,
unknown. This study sought to determine the incidence of development of
new aneurysms in previously nonaneurysmal popliteal arterial segments after
repair of an index PAA. The study was based on analysis of the Swedish
Vascular Registry. (Every citizen in Sweden has a unique personal identity
code that can be used in vascular surgical research.)
Between 1987 and 2002, 571 patients (717 legs) in Sweden had a
primary operation for PAA. Analysis for this study began in January 2005.
Data were crosschecked against the national population registry and indi-
cated 337 patients had undergone PAA repair during the study period and
were alive in January 2005. Patients were then assessed for the presence of
additional aneurysms at the time of their index PAA repair and were asked to
participate in a telephone interview and a re-examination. Of these, 240
patients agreed, and 190 were re-examined by ultrasonography at a medium
of 7 years (range, 2.9-18.7 years) after their index PAA repair.
At the time of the PAA repair, the number of patients with at least one
aneurysm, in addition to the index PAA, was 108 (56.8%) at the index
operation, and 131 (68.0%) at re-examination. The number of additional
aneurysms increased from 244 to 346 (an increase of 41.8%). Among the 82
patients who had an isolated PAA at the index operation, a new aneurysm
was detected in 23 at the time of their follow-up ultrasound study.
Patients in whom new aneurysms developed tended to be older (P 
.004). The presence of bilateral PAA at the index operation was associ-
ated with a later development of an abdominal aortic aneurysm (P 
.004). Increased age and hypertension at the time of the index operation
were associated with multianeurysmal disease at any time (P  .004 and
P  .012 respectively).
Venous bypass grafts were used to treat 138 of the legs, and six (4.3%)
developed aneurysm degeneration of the venous bypass graft. Within 3 years
of the initial PAA repair, no normal arterial segments had developed suffi-
cient aneurysmal degeneration that required surgery. Overall, an additional
102 aneurysms developed in 74 patients, and only 59 of the 190 subjects
re-examined did not develop an additional aneurysm.
Comment: This study indicates new aneurysm development in
patients with PAA is frequent. Because no patient developed a new aneurysm
that required surgery 3 years of the index operation, it would seem that a
practical plan for follow-up would be to reinvestigate patients with PAAs for
new aneurysms every 3 years, beginning 3 years after the initial popliteal
aneurysm repair.
Do current outcomes justify more liberal use of revascularization for
vasculogenic claudication? A single-center experience of 1000 consec-
utively treated limbs
Taylor SM, Kalbaugh CA, Healy NG, et al. J Am Coll Surg 2008;206:
1053-64.
Conclusions: In contemporary practice, treatment of claudication is
safe, effective, and predominantly endovascular.
Summary: This is a retrospective review of 1000 limbs in 669 patients
treated for what was determined to be medically refractory vasculogenic
claudication. The authors assess procedural complication rates, patency of
reconstructions, maintenance of ambulatory status, maintenance of inde-
pendent living, survival, symptom resolution, symptom recurrence, and limb
salvage. Of the 1000 limbs treated, aortoiliac disease was treated in 70.1%
and infrainguinal occlusive disease in 29.9%. Endovascular therapy was used
in 64.3% of the limbs treated and open surgery in 35.7%. The 30-day
complication rate was 7.5%. The authors noted no difference in complica-
tion rates comparing types of treatment or level of disease. At 1 and 5 years,
reconstruction primary patency was 87.7% and 70.8%, secondary patency
was 97.8% and 93.9%, survival was 94.4% and 76.9%, and limb salvage was
100% and 98.8%, respectively. Symptom resolution occurred in 78.8% and
recurrence in 18.1%. There was slightly higher resolution and recurrence
noted in patients treated with endovascular therapy.
Comment: You have to admire the fact that this group of surgeons
keeps track of what they do and tries to report their results. Unfortunately,
the way they report their results is not all that useful. Patients were not
stratified by degree of claudication, TransAtlantic Inter-Society Consensus
lesions, prehemodynamic and posthemodynamic status, or the occurrence of
single-level or multilevel disease. We also have no idea about who was not
treated. Nevertheless, it does appear that if you are willing to spend a lot of
money, you can treat a lot of patients with claudication and you won’t hurt
many of them very much.
Fistula elevation procedure: Experience with 295 consecutive cases
during a 7-year period
Bronder CM, Cull DL, Kuper SG, et al. J AmColl Surg 2008;206:1076-82.
Conclusion: Elevation of an autogenous fistula that is otherwise too
deep or tortuous for access is a valuable adjunct that improves ultimate
utilization of autogenous arteriovenous fistulas in hemodialysis access.
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